FETAL GOITRE IN MATERNAL GRAVES' DISEASE

Area of Science:

• Endocrinology
• Maternal-Fetal Medicine
• Neonatology

Background:

• Fetal goitre affects approximately 1 in 5,000 births, frequently associated with maternal Graves' disease.
• Pathogenesis involves transplacental transfer of thyroid-stimulating antibodies or anti-thyroid drugs.
• Goitre complications arise from size and associated fetal thyroid dysfunction (hypo- or hyperthyroidism).

Discussion:

• Fetal ultrasound reliably detects goitre but cannot differentiate between fetal hypothyroidism and hyperthyroidism.
• Accurate diagnosis of fetal thyroid status requires maternal condition assessment and potentially cordocentesis.
• Management strategies focus on maternal anti-thyroid drug dosage adjustment as first-line therapy.

Key Insights:

• Distinguishing fetal thyroid dysfunction requires integrated maternal and fetal assessments.
• Maternal anti-thyroid drug management is crucial for fetal well-being.
• Delivery is typically at term, with Cesarean section indicated for large goitres.

Outlook:

• Further research into non-invasive methods for assessing fetal thyroid function is warranted.
• Optimizing maternal treatment protocols can mitigate fetal goitre complications.
• Improved understanding of transplacental antibody dynamics may refine therapeutic approaches.